Vandetanib-treated tumors showed a decrease at both mRNA and protein level of mechanistic targets of rapamycin (mTOR), hypoxia-inducible factor-1 (HIF-1) alpha, and vascular endothelial growth factor (VEGF), genes allowing survival, proliferation and tumor growth and all up-regulated in BC. The gene discussed is MTOR; the disease is neoplasm.